Related Experiment Videos
Effect of prophylactic, low dose cephalexin on fecal and vaginal bacteria
Abstract:
Effective prophylactic antimicrobial therapy for recurrent urinary tract infections depends upon the creation of minimal antimicrobial resistance in the fecal and vaginal flora. Cephalexin is known to be useful for prophylaxis clinically but substantial resistance has been reported in vaginal and rectal Escherichia coli at doses of 2 gm. per day. The effect of 250 mg. cephalexin nightly was studied in 23 women with recurrent bacteriuria who were treated for 6 months. Of the 23 patients 22 remained free of infection for 132 months of observation. Despite heavy carriage of Escherichia coli in the rectal and vaginal reservoirs during therapy, Escherichia coli resistant to 32 micrograms per ml. cephalexin did not occur. These observations explain the prophylactic effectiveness of cephalexin when used in small amounts of single nightly dosages.
Insights
Low-dose nightly cephalexin (250 mg) effectively prevents recurrent urinary tract infections (UTIs) by minimizing antimicrobial resistance in gut flora. This approach proved highly successful in a 6-month study of women with recurrent UTIs.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Recurrent urinary tract infections (UTIs) necessitate effective antimicrobial prophylaxis.
- Antimicrobial resistance in fecal and vaginal flora is a key challenge.
- High-dose cephalexin (2 gm/day) has shown resistance in Escherichia coli.
Purpose of the Study:
- To evaluate the efficacy of low-dose nightly cephalexin (250 mg) for preventing recurrent UTIs.
- To assess the impact of low-dose cephalexin on antimicrobial resistance in Escherichia coli.
- To determine the long-term infection-free rates in women receiving prophylactic cephalexin.
Main Methods:
- A prospective study involving 23 women with recurrent bacteriuria.
- Treatment with 250 mg cephalexin administered nightly for 6 months.
- Monitoring of infection status and antimicrobial resistance in fecal and vaginal flora.
Main Results:
- 22 out of 23 patients remained infection-free for a median of 132 months.
- No development of cephalexin-resistant Escherichia coli (≥32 µg/mL) was observed.
- Heavy carriage of Escherichia coli persisted in rectal and vaginal reservoirs during therapy.
Conclusions:
- Low-dose nightly cephalexin (250 mg) is effective for prophylactic treatment of recurrent UTIs.
- This regimen minimizes the emergence of antimicrobial resistance in key flora.
- Single, small, nightly dosages of cephalexin offer a viable strategy for UTI prevention.